New Alzheimer's Combo Drug Launched

Share this content:
Namzaric Launched for Alzheimer's Disease
Namzaric Launched for Alzheimer's Disease

Actavis announced that Namzaric (memantine HCl extended-release and donepezil HCl) capsules have launched for the treatment of moderate to severe Alzheimer's disease in patients stabilized on memantine HCl and donepezil HCl.

Namzaric combines memantine (Namenda), a NMDA receptor antagonist and donepezil (Aricept), an acetylcholinesterase inhibitorase inhibitor. Memantine is presumed to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive NMDA receptor antagonist which bind preferentially to the NMDA receptor-operated cation channels.

Donepezil is presumed to exert its therapeutic effect by enhancing cholinergic function through increasing the concentration of acetylcholine in the central nervous system through reversible inhibition of its hydrolysis by acetylcholinesterase.

Namzaric is available as 14mg/10mg and 28mg/10mg strength capsules in 30- and 90-count bottles.The drug was initially approved by the FDA in December.

For more information, visit Namzaric.com.

You must be a registered member of Psychiatry Advisor to post a comment.

Sign Up for Free e-newsletters